Clinigen partners with Neuraltus to provide access to new ALS drug in Europe
The companies will start a managed access program in selected countries for NP001, Neuraltus’ investigational therapy for ALS. Coverage is planned to be expanded in the next year.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.